217 related articles for article (PubMed ID: 23664819)
1. Intraductal therapy of ductal carcinoma in situ: a presurgery study.
Mahoney ME; Gordon EJ; Rao JY; Jin Y; Hylton N; Love SM
Clin Breast Cancer; 2013 Aug; 13(4):280-6. PubMed ID: 23664819
[TBL] [Abstract][Full Text] [Related]
2. The effect of size and polymer architecture of doxorubicin-poly(ethylene) glycol conjugate nanocarriers on breast duct retention, potency and toxicity.
Gu Z; Gao D; Al-Zubaydi F; Li S; Singh Y; Rivera K; Holloway J; Szekely Z; Love S; Sinko PJ
Eur J Pharm Sci; 2018 Aug; 121():118-125. PubMed ID: 29698706
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
4. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
[TBL] [Abstract][Full Text] [Related]
6. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions.
Chantzi NI; Palaiologou M; Stylianidou A; Goutas N; Vassilaros S; Kourea HP; Dhimolea E; Mitsiou DJ; Tiniakos DG; Alexis MN
J Cancer Res Clin Oncol; 2014 Jun; 140(6):1057-66. PubMed ID: 24671226
[TBL] [Abstract][Full Text] [Related]
8. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
[TBL] [Abstract][Full Text] [Related]
9. The impact of field cancerization on the extent of duct carcinoma in situ (DCIS) in breast tissue after conservative excision.
Asioli S; Morandi L; Cavatorta C; Cucchi MC; Foschini MP
Eur J Surg Oncol; 2016 Dec; 42(12):1806-1813. PubMed ID: 27546014
[TBL] [Abstract][Full Text] [Related]
10. Management of ductal carcinoma in situ with nipple discharge. Intraductal spreading of carcinoma is an unfavorable pathologic factor for breast-conserving surgery.
Ohuchi N; Furuta A; Mori S
Cancer; 1994 Aug; 74(4):1294-302. PubMed ID: 8055451
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
[TBL] [Abstract][Full Text] [Related]
12. Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer?
Choi DX; Eaton AA; Olcese C; Patil S; Morrow M; Van Zee KJ
Ann Surg Oncol; 2013 Apr; 20(4):1302-10. PubMed ID: 23161115
[TBL] [Abstract][Full Text] [Related]
13. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery.
Langhans L; Jensen MB; Talman MM; Vejborg I; Kroman N; Tvedskov TF
JAMA Surg; 2017 Apr; 152(4):378-384. PubMed ID: 28002557
[TBL] [Abstract][Full Text] [Related]
14. Clinic-Pathological Features of Breast Ductal Carcinoma
Zheng J; Zhou T; Li F; Shi J; Zhang L
Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
[No Abstract] [Full Text] [Related]
15. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
[TBL] [Abstract][Full Text] [Related]
16. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
Sanders ME; Schuyler PA; Dupont WD; Page DL
Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
[TBL] [Abstract][Full Text] [Related]
17. Impact of breast MRI in women eligible for breast conservation surgery and intra-operative radiation therapy.
Paudel N; Bethke KP; Wang LC; Strauss JB; Hayes JP; Donnelly ED
Surg Oncol; 2018 Mar; 27(1):95-99. PubMed ID: 29549911
[TBL] [Abstract][Full Text] [Related]
18. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy.
Al-Zubaydi F; Gao D; Kakkar D; Li S; Adler D; Holloway J; Szekely Z; Gu Z; Chan N; Kumar S; Love S; Sinko PJ
J Control Release; 2020 Jul; 323():71-82. PubMed ID: 32302762
[TBL] [Abstract][Full Text] [Related]
19. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
[TBL] [Abstract][Full Text] [Related]
20. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
